Don't MissASCO in 30: 5-year Keytruda data & winners and losers By Sharon Begley and Adam Feuerstein June 2, 2018 Reprints ASCO in 30: 5-year Keytruda data & winners and losers About the Authors Reprints Sharon Begley Senior Writer, Science and Discovery (1956-2021) Sharon covered science and discovery. @sxbegle Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast. [email protected] @adamfeuerstein
Don't Miss STAT Staff Introducing the 2023 STATUS List, the definitive accounting of leaders in the life sciences
Health Tech Brittany Trang and Casey Ross STAT Plus: ‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4 AI to its medical note-taking tool
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
